SCHEMBL26964398

SCHEMBL26964398

Cc1cccnc1S(=O)(=O)Nc1cccc2c1N(C)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 1/20 0.43
▸ SLC40A1 Q9NP59 6/20 0.41
▸ TDP1 Q9NUW8 6/20 0.38
▸ KMT2A Q03164 6/20 0.38
▸ MEN1 O00255 4/20 0.38
▸ NPSR1 Q6W5P4 4/20 0.37
▸ LMNA P02545 3/20 0.37
▸ RECQL P46063 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ HTT P42858 3/20 0.37
▸ OPRK1 P41145 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ MITF O75030 1/20 0.37
▸ S1PR4 O95977 1/20 0.37
▸ S1PR1 P21453 1/20 0.37
▸ AGTR1 P30556 1/20 0.37
▸ CKS1B P61024 1/20 0.37
▸ SKP2 Q13309 1/20 0.37
▸ GLO1 Q04760 1/20 0.37
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30553464 1.00 KMO (0.43) KMOSLC40A1TDP1KMT2AMEN1
SCHEMBL30925585 0.93 ALDH1A1 (0.40) KMOSLC40A1TDP1KMT2AMEN1
SCHEMBL29800729 0.83 TP53 (0.38) SLC40A1TDP1KMT2AMEN1NPSR1
SCHEMBL26964478 0.83 TP53 (0.38) SLC40A1TDP1KMT2AMEN1NPSR1
SCHEMBL29800820 0.82 ALDH1A1 (0.43) SLC40A1TDP1KMT2AMEN1NPSR1
SCHEMBL26964182 0.82 ALDH1A1 (0.43) SLC40A1TDP1KMT2AMEN1NPSR1
SCHEMBL26964253 0.78 SLC40A1 (0.42) SLC40A1TDP1KMT2AMEN1NPSR1
SCHEMBL29800777 0.78 SLC40A1 (0.42) SLC40A1TDP1KMT2AMEN1NPSR1
SCHEMBL30925408 0.76 ALDH1A1 (0.40) SLC40A1TDP1KMT2AMEN1NPSR1
SCHEMBL26964299 0.76 NPSR1 (0.44) SLC40A1NPSR1LMNARECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 — — EP disclosed
WO-2022173727-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 KMO 3789/4885SLC40A1 3357/4885TDP1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback